KRAS and neoplasm: In this study, the combination of a MEK1/2 inhibitor (AZD6244) and a PI3K inhibitor (BEZ235) in tumor-bearing mice showed initial reduction and subsequent inhibition of tumor growth, suggesting that this combination therapy might enhance anti-tumor activity in KRAS mutant cells [68].